Nonclinical Disposition and Bioanalysis Co-op - Spring 2023
At Bristol Myers Squibb, we are inspired by a single vision – transforming patients’ lives through science. In oncology, hematology, immunology and cardiovascular disease – and one of the most diverse and promising pipelines in the industry – each of our passionate colleagues contribute to innovations that drive meaningful change. We bring a human touch to every treatment we pioneer. Join us and make a difference.
The Nonclinical Disposition and Bioanalysis organization (NDB) is responsible for supporting the translational ADME, PK/PD, and ADA bioanalysis for biotherapeutics.
The 6-month paid Co-op opportunity in the Nonclinical Disposition and Bioanalysis organization (NDB) at Bristol Myers Squibb (BMS) will focus on i) identifying predictive biomarkers of immunogenicity using in silico tools and genomic data mining and associations with clinical data and ii) confirm the in silico derived biomarker with in vitro generated outputs for further elucidation of the mechanisms of activation of immune response to biologics. Immunogenicity towards therapeutic proteins poses a significant risk factor for safety and efficacy and is considered a priority to address from a regulatory perspective. Significant effort is being undertaken to mitigate and measure the immunogenicity of their products during development. Despite potential immunogenicity, many biologics are approved because of the unmet needs and skewed risk-benefit evaluations. Yet, there are no reliable methods to predict the risk for developing an immune response, as well as monitoring the onset, incidence, and frequency of immunogenicity- especially related to patient-derived attributes.
The goal of this project is to develop bioinformatics tools to evaluate the personalized immunogenicity risk of biologics from the patient’s perspective and ways to mitigate the risk in the clinic. This project will involve cross-functional collaborations within BMS and external partners to characterize the immune responses to CAR-T cells and biologics using bioinformatic tools and various laboratory methodologies.
Key Responsibilities include:
- The program is organized to ensure a Co-op student gain valuable industry and functional expertise
- The intern will work closely with a Ph.D. principal investigator
- The experience will include developing expertise in bioinformatics-based data mining to establish immune-based biomarkers and lab techniques for evaluating outputs from immune cell-based assays
- Interns will contribute meaningfully to their teams through challenging assignments and have the opportunity to collaborate with other functional groups within discovery and NDB
- Learning the principles and procedures to work safely in a biological lab
- Utilize molecular biology, biochemistry, and immunology concepts to understand immunogenicity
- Perform ligand binding assays; work with cell culture and primary cells isolated from human blood
- The proper procedure for keeping a lab notebook
- The candidates who are considered for full-time Co-op hire demonstrate a desire to learn and make an impact on the biopharma industry
Duration: 6 months
Hours per week: 20-40 hours/week
Job function: Research
Job role: Co-op opportunity in the Nonclinical Disposition and Bioanalysis department
Around the world, we are passionate about making an impact on the lives of patients with serious diseases. Empowered to apply our individual talents and diverse perspectives in an inclusive culture, our shared values of passion, innovation, urgency, accountability, inclusion and integrity bring out the highest potential of each of our colleagues.
Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives.
Physical presence at the BMS worksite or physical presence in the field is an essential job function of this role which the Company deems critical to collaboration, innovation, productivity, employee well-being and engagement, and enhances the Company culture.
To protect the safety of our workforce, customers, patients and communities, the policy of the Company requires all employees and workers in the U.S. and Puerto Rico to be fully vaccinated against COVID-19, unless they have received an exception based on an approved request for a medical or religious reasonable accommodation. Therefore, all BMS applicants seeking a role located in the U.S. and Puerto Rico must confirm that they have already received or are willing to receive the full COVID-19 vaccination by their start date as a qualification of the role and condition of employment. This requirement is subject to state and local law restrictions and may not be applicable to employees working in certain jurisdictions such as Montana. This requirement is also subject to discussions with collective bargaining representatives in the U.S.
Our company is committed to ensuring that people with disabilities can excel through a transparent recruitment process, reasonable workplace adjustments and ongoing support in their roles. Applicants can request an approval of accommodation prior to accepting a job offer. If you require reasonable accommodation in completing this application or if you are applying to a role based in the U.S. or Puerto Rico and you believe that you are unable to receive a COVID-19 vaccine due to a medical condition or sincerely held religious belief, during or any part of the recruitment process, please direct your inquiries to firstname.lastname@example.org. Visit careers.bms.com/eeo-accessibility to access our complete Equal Employment Opportunity statement.
BMS will consider for employment qualified applicants with arrest and conviction records, pursuant to applicable laws in your area.
Any data processed in connection with role applications will be treated in accordance with applicable data privacy policies and regulations.